UNIVERSITY OF FLORIDA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1853-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ufl.edu
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
- Conditions
- Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 1
- Interventions
- Genetic: All Participants
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 800
- Registration Number
- NCT01060371
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: < 15% risk of + LNRadiation: > 15% risk of + LN
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 77
- Registration Number
- NCT01040624
- Locations
- 🇺🇸
University of Florida Proton Therapy Institute, Jacksonville, Florida, United States
Blood Flow, Muscle Regeneration and Sarcopenia
- Conditions
- Sarcopenia
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 68
- Registration Number
- NCT01035060
- Locations
- 🇺🇸
Aging and Rehabilitation Research Center, Gainesville, Florida, United States
Biological Effects of Weight Loss In Older, Obese Women
- Conditions
- ObesitySarcopenia
- Interventions
- Behavioral: Lifestyle CounselingOther: Educational Control
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 34
- Registration Number
- NCT01032733
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver DiseaseType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 24
- Registration Number
- NCT01006889
- Locations
- 🇺🇸
The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio, Texas, United States
Patient Comfort With Vascular Closure
- Conditions
- Vascular Closure
- Interventions
- Device: Mynx Vascular Closure DeviceDevice: AngioSeal Vascular Closure Device
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 64
- Registration Number
- NCT00998023
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Insulin detemir and pre-meal insulin aspart.Drug: Long-acting bedtime insulin detemir (Levemir)
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00998335
- Locations
- 🇺🇸
The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio, Texas, United States
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
- Conditions
- Nonalcoholic Fatty Liver DiseaseType 2 Diabetes MellitusNonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 176
- Registration Number
- NCT00994682
- Locations
- 🇺🇸
Bartter Research Unit, Audie L Murphy VA Hospital, San Antonio, Texas, United States
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
- Conditions
- Pompe Disease
- Interventions
- Drug: rAAV1-CMV-GAA (study agent) AdministrationOther: RMST
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 9
- Registration Number
- NCT00976352
- Locations
- 🇺🇸
Shands at the University of Florida, Gainesville, Florida, United States
Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents
- Conditions
- Gastrointestinal Diseases
- Interventions
- Procedure: Self-expandable stent placement via endoscopy
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 23
- Registration Number
- NCT00968552
- Locations
- 🇺🇸
Shands UF endoscopy Center, Gainesville, Florida, United States